Therefore, we hypothesized that the difference in immunophenotype between BRCA1- and BRCA2-deficient breast cancers may be attributed to PTEN loss, such as that mediated by inactivating PTEN gene mutations. The gene discussed is BRCA2; the disease is breast cancer.